COVID-19 RecurrenceNCT05470426
Viral Excretion Among COVID-19 Omicron Recurrence Patients
An observational study of COVID-19 Recurrence and Surface Contamination, run by RenJi Hospital at 1 site in China.
Trial summary
The study analyzes the viral nucleic acid excretion and its influencing factors of SARS-COV-2 Omicron recurrence patients. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COVID-19 Recurrence, Surface Contamination
- What is being tested?
- COVID-19 Omicron Recurrence
- How many people
- 35 participants
- Where
- 1 siteChina
- Study dates
- Jul 2022to Aug 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with COVID-19 Omicron Recurrence
Who may be able to join
- Patients with nucleic acid detection N gene and ORF gene Ct value < 40 after discharge from hospital
- Being able to provide basic information, living habits, vaccination information, admission information
Who cannot join
- Single gene target positive
- Patients with incomplete baseline data
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Renji Hospital
Shanghai, 200123
Ya Yang, yangya@renji.com
About this study
Official title: Viral Excretion and Its Influencing Factors Among COVID-19 Omicron Recurrence Patients
The study analyzes the viral nucleic acid excretion and its influencing factors of SARS-COV-2 Omicron recurrence patients.
- Conditions
- COVID-19 Recurrence, Surface Contamination
- Being tested
- COVID-19 Omicron Recurrence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
COVID-19 Omicron RecurrenceOther
COVID-19 Omicron Recurrence
What is being measured
The primary outcome is the main question the study is designed to answer.
COVID-19 Omicron Recurrence
COVID-19 Omicron Recurrence
Measured: Six months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2022
- Study startJul 2022 (estimated)
- Primary completionJul 2023 (estimated)
- Study completionAug 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19 RecurrenceStudies of the same condition, open and under way.
- More trials run by RenJi HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- RenJi Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05470426
- Sponsor's protocol ID
- IIT-2022-0102
- Status last verified
- Jul 2022
- First submitted
- 20 Jul 2022
- Last updated
- 22 Jul 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Viral Excretion and Its Influencing Factors Among COVID-19 Omicron Recurrence Patients
- ClinicalTrials.gov ID
- NCT05470426
- Acronym / sponsor ID
- IIT-2022-0102
- Conditions
- COVID-19 Recurrence, Surface Contamination
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- RenJi HospitalUniversity, hospital or other
- Study start
- Jul 2022 (estimated)
- Primary completion
- Jul 2023 (estimated)
- Study completion
- Aug 2023 (estimated)
- First posted
- 22 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study analyzes the viral nucleic acid excretion and its influencing factors of SARS-COV-2 Omicron recurrence patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with COVID-19 Omicron Recurrence
Key inclusion criteria (2 listed)
- Patients with nucleic acid detection N gene and ORF gene Ct value < 40 after discharge from hospital
- Being able to provide basic information, living habits, vaccination information, admission information
Key exclusion criteria (2 listed)
- Single gene target positive
- Patients with incomplete baseline data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| COVID-19 Omicron RecurrenceCOVID-19 Omicron Recurrence | Other | – |
Primary outcome
COVID-19 Omicron Recurrence
Time frame: Six months
COVID-19 Omicron Recurrence
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2022.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 Recurrence and Surface Contamination, run by RenJi Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ya Yang, PhD (68383362, yangya@renji.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
COVID-19 Omicron Recurrence (time frame: Six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2022; AzTrials last refreshed its copy on 7 Nov 2026.